INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,139,000 | -62.3% | 18,100 | -25.8% | 0.60% | +70.9% |
| Q4 2019 | $3,023,000 | -34.6% | 24,400 | -65.0% | 0.35% | -40.1% |
| Q3 2019 | $4,625,000 | -16.6% | 69,700 | 0.0% | 0.59% | +53.9% |
| Q2 2019 | $5,546,000 | -47.7% | 69,700 | -26.5% | 0.38% | -21.8% |
| Q1 2019 | $10,604,000 | +100.9% | 94,800 | +50.7% | 0.49% | +58.9% |
| Q2 2018 | $5,277,000 | -37.2% | 62,900 | -53.9% | 0.31% | -42.4% |
| Q1 2018 | $8,397,000 | -20.6% | 136,500 | -24.6% | 0.54% | -5.5% |
| Q4 2017 | $10,580,000 | +44.8% | 181,110 | +43.9% | 0.57% | +44.6% |
| Q3 2017 | $7,307,000 | +3430.0% | 125,900 | +4096.7% | 0.39% | +734.0% |
| Q3 2013 | $207,000 | – | 3,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |